Neuroendocrine carcinoma

Section editor
	Unfilled If you are interested in this role, please contact us at [email protected].

2 regimens on this page 2 variants on this page

Note: these are regimens tested in histology-specific populations, please see the main NET page for other regimens.

Guidelines

Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only.

NCCN

• NCCN does not currently have guidelines at this granular level; please see NCCN Guidelines - Neuroendocrine and Adrenal Tumors.

Advanced disease, all lines of therapy

Cisplatin & Etoposide (EP)

EP: Etoposide and Platinol (Cisplatin)

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Morizane et al. 2022 (TOPIC-NEC)	2014-08-08 to 2020-03-06	Phase 3 (E-switch-ic)	IP	Did not meet primary endpoint of OS

Chemotherapy

• Cisplatin (Platinol) 80 mg/m² IV once on day 1
• Etoposide (Vepesid) 100 mg/m² IV once per day on days 1 to 3

21-day cycles

References

1. TOPIC-NEC: Morizane C, Machida N, Honma Y, Okusaka T, Boku N, Kato K, Nomura S, Hiraoka N, Sekine S, Taniguchi H, Okano N, Yamaguchi K, Sato T, Ikeda M, Mizuno N, Ozaka M, Kataoka T, Ueno M, Kitagawa Y, Terashima M, Furuse J. Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial. JAMA Oncol. 2022 Oct 1;8(10):1447-1455. link to original article link to PMC article contains dosing details in manuscript PubMed UMIN000014795

Cisplatin & Irinotecan (IC)

IP: Irinotecan, Platinol (Cisplatin)

Regimen

Study	Dates of enrollment	Evidence	Comparator	Comparative Efficacy
Morizane et al. 2022 (TOPIC-NEC)	2014-08-08 to 2020-03-06	Phase 3 (E-switch-ic)	EP	Did not meet primary endpoint of OS

Chemotherapy

• Cisplatin (Platinol) 60 mg/m² IV once on day 1
• Irinotecan (Camptosar) 60 mg/m² IV once per day on days 1, 8, 15

28-day cycles

References

1. TOPIC-NEC: Morizane C, Machida N, Honma Y, Okusaka T, Boku N, Kato K, Nomura S, Hiraoka N, Sekine S, Taniguchi H, Okano N, Yamaguchi K, Sato T, Ikeda M, Mizuno N, Ozaka M, Kataoka T, Ueno M, Kitagawa Y, Terashima M, Furuse J. Effectiveness of Etoposide and Cisplatin vs Irinotecan and Cisplatin Therapy for Patients With Advanced Neuroendocrine Carcinoma of the Digestive System: The TOPIC-NEC Phase 3 Randomized Clinical Trial. JAMA Oncol. 2022 Oct 1;8(10):1447-1455. link to original article link to PMC article contains dosing details in manuscript PubMed UMIN000014795